挽救性转移灶导向治疗与选择性淋巴结放疗对寡复发淋巴结前列腺癌患者健康相关生活质量的影响:PEACE V-STORM随机试验二次分析
这项随机2期PEACE V-STORM试验的二次分析,纳入190例PET检测到异时性淋巴结寡复发的前列腺癌患者,比较转移灶导向治疗(MDT)与选择性盆腔淋巴结放疗(ENRT)联合6个月雄激素剥夺治疗(ADT)的健康相关生活质量(HRQoL)。中位随访50个月,QLQ-C30和QLQ-PR25量表多数领域无显著差异;仅ENRT组24个月时躯体功能下降更明显,MDT组12个月时情绪功能下降更明显,ENRT组18个月时肠道症状稍好但前后无差异。
要点
- MDT与ENRT联合ADT在多数HRQoL领域无显著差异
- ENRT组24个月躯体功能下降更明显,MDT组12个月情绪功能下降更明显
- 两组性活动下降和ADT相关症状在前6个月相似,12个月恢复基线
核心结论
- 与医生报告的治疗相关不良事件一致,HRQoL分析显示ENRT与MDT之间无显著差异。
研究设计与样本
- 随机2期开放标签PEACE V-STORM试验(NCT03569241)的二次分析,196例随机患者中190例可评估(MDT组97例,ENRT组93例),使用EORTC QLQ-C30和QLQ-PR25问卷在4年期间评估HRQoL。
主要发现
- 中位随访50个月(四分位距42-58),QLQ-C30评分除ENRT组24个月时躯体功能下降更明显(平均下降-7.7 vs -1.3)和MDT组12个月时情绪功能下降更明显(平均下降5.8 vs -0.4,p=0.034)外,两组无显著差异。
- QLQ-PR25评分除ENRT组18个月时肠道症状稍好(前后无差异)外,无显著差异。
- 前6个月性活动下降和ADT相关症状增加在两组间相当,12个月时恢复基线。
关键数值与推荐
- ENRT组24个月躯体功能平均下降-7.7,MDT组-1.3。
- MDT组12个月情绪功能平均下降5.8,ENRT组-0.4(p=0.034)。
临床怎么用
- 对于PET检测到的异时性淋巴结寡复发前列腺癌,MDT与ENRT联合6个月ADT在HRQoL上总体无显著差异,可作为治疗选择时的参考。
局限性
- 本文为二次分析,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For prostate cancer patients with metachronous nodal oligorecurrences detected by positron emission tomography, the randomized phase 2 PEACE V-STORM trial (NCT03569241) demonstrated that, compared with metastasis-directed therapy (MDT), elective nodal pelvic radiotherapy (ENRT) in combination with 6 mo of androgen deprivation therapy (ADT) improved locoregional disease control and metastasis-free survival. In the 190 evaluable patients (MDT: 97 and ENRT: 93) of the 196 randomized in the study, health-related quality of life (HRQoL) was assessed by European Organization for Research and Treatment of Cancer QLQ-C-30 and QLQ-PR-25 questionnaires over a 4-yr period as a part of a statistically defined quality of life analysis. During a median follow-up of 50 mo (interquartile range 42-58), QLQ-C30 scores showed no significant differences between MDT and ENRT, except for worse physical functioning at month 24 in the ENRT group (mean decline -7.7 vs -1.3) and worse emotional functioning at month 12 in the MDT group (mean decline 5.8 vs -0.4, p = 0.034). No significant differences in QLQ-PR25 scores were observed, except slightly better bowel symptoms at 18 mo for ENRT, but with no difference before or after. The decline in sexual activity and increase in ADT-related symptoms during the first 6 mo were comparable between arms, returning to baseline by month 12. Consistent with physician-reported treatment-related adverse events, HRQoL analyses show no significant differences between ENRT and MDT.
引用
- Zilli T, Siva S, Brabrand S, et al. Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial. Eur Urol Oncol. 2026. PMID: 41565552. doi:10.1016/j.euo.2026.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。